Wave Life Sciences, Inc. (WVE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q4 '15: 152K Q1 '17: 1.9M Q2 '17: 2.5M Q3 '17: 3.5M Q4 '17: 3.9M Q1 '18: 4.9M Q2 '18: 8.7M Q3 '18: 11.9M Q4 '18: 14.4M Q1 '19: 16M Q2 '19: 18.8M Q3 '19: 17.2M Q4 '19: 16M Q1 '20: 17.1M Q2 '20: 12.5M Q3 '20: 13M Q4 '20: 20.1M Q1 '22: 42.7M Q2 '22: 40.3M Q3 '22: 4.2M Q4 '22: 3.6M Q1 '23: 14.8M Q2 '23: 36.6M Q3 '23: 85.5M Q4 '23: 113.3M Q1 '24: 112.9M Q2 '24: 110.5M Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '22 Q2 '23 Q2 '24

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '16: -44M Q4 '16: -55.3M Q1 '17: -67.6M Q2 '17: -80.6M Q3 '17: -89.7M Q4 '17: -102.4M Q1 '18: -118M Q2 '18: -129.9M Q3 '18: -141.7M Q4 '18: -159.5M Q1 '19: -171.7M Q2 '19: -180.8M Q3 '19: -196.7M Q4 '19: -208.3M Q1 '20: -210.3M Q2 '20: -203.4M Q3 '20: -183.6M Q4 '20: -153.4M Q1 '21: -146.9M Q2 '21: -148M Q3 '21: -121.2M Q4 '21: -127M Q1 '22: -121.6M Q2 '22: -124M Q3 '22: -155.3M Q4 '22: -162.7M Q1 '23: -154.9M Q2 '23: -136.2M Q3 '23: -92.9M Q4 '23: -68M Q1 '24: -72.2M Q2 '24: -83.7M Q3 '24: -152.1M Q4 '24: -110.4M Q1 '25: -125.7M Q2 '25: -143.5M Q3 '25: -135.9M Q4 '25: -215.4M Q1 '26: -196.9M Q2 '26: -217.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '16: -44M Q4 '16: -55.4M Q1 '17: -68.7M Q2 '17: -81.7M Q3 '17: -89.6M Q4 '17: -102M Q1 '18: -116.1M Q2 '18: -127.4M Q3 '18: -139.6M Q4 '18: -146.7M Q1 '19: -155.6M Q2 '19: -161.7M Q3 '19: -174.8M Q4 '19: -193.6M Q1 '20: -196.9M Q2 '20: -195.5M Q3 '20: -177.9M Q4 '20: -149.9M Q1 '21: -144.9M Q2 '21: -143.1M Q3 '21: -116.2M Q4 '21: -122.2M Q1 '22: -117.6M Q2 '22: -120.1M Q3 '22: -152.9M Q4 '22: -161.8M Q1 '23: -151.4M Q2 '23: -131.2M Q3 '23: -85M Q4 '23: -57.5M Q1 '24: -61.7M Q2 '24: -73.5M Q3 '24: -142.5M Q4 '24: -97M Q1 '25: -112.3M Q2 '25: -129.9M Q3 '25: -121.9M Q4 '25: -204.4M Q1 '26: -183.6M Q2 '26: -202.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '16: -25.2M Q4 '16: -31.9M Q1 '17: -42.2M Q2 '17: -62.6M Q3 '17: -74.2M Q4 '17: -83.7M Q1 '18: -98.7M Q2 '18: -7.2M Q3 '18: -12.8M Q4 '18: -22.9M Q1 '19: -40.8M Q2 '19: -145.1M Q3 '19: -159.8M Q4 '19: -188.2M Q1 '20: -164.1M Q2 '20: -169.3M Q3 '20: -145.8M Q4 '20: -116M Q1 '21: -134.1M Q2 '21: -105.4M Q3 '21: -113.4M Q4 '21: -89M Q1 '22: -84.5M Q2 '22: -103.9M Q3 '22: -101.4M Q4 '22: -127.8M Q1 '23: -2.4M Q2 '23: -10.8M Q3 '23: -19.6M Q4 '23: -19.4M Q1 '24: -138.4M Q2 '24: -128.6M Q3 '24: -140.6M Q4 '24: -151M Q1 '25: -180.6M Q2 '25: -199.2M Q3 '25: -197.4M Q4 '25: -187.5M Q1 '26: -184M Q2 '26: -191.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '16: -29.1M Q4 '16: -37.4M Q1 '17: -50.7M Q2 '17: -75.8M Q3 '17: -91.7M Q4 '17: -102.6M Q1 '18: -115.1M Q2 '18: -20M Q3 '18: -23.4M Q4 '18: -32.8M Q1 '19: -50.1M Q2 '19: -154.1M Q3 '19: -165.8M Q4 '19: -192.1M Q1 '20: -168.1M Q2 '20: -171.8M Q3 '20: -147.9M Q4 '20: -117.3M Q1 '21: -135M Q2 '21: -106.4M Q3 '21: -114.5M Q4 '21: -89.6M Q1 '22: -85.2M Q2 '22: -104.7M Q3 '22: -102.5M Q4 '22: -129.1M Q1 '23: -4M Q2 '23: -12M Q3 '23: -20.6M Q4 '23: -20.5M Q1 '24: -139.4M Q2 '24: -129.6M Q3 '24: -141.8M Q4 '24: -152M Q1 '25: -181.3M Q2 '25: -200.1M Q3 '25: -198.2M Q4 '25: -188.2M Q1 '26: -185M Q2 '26: -193.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '21: 50M Q3 '21: 50.7M Q1 '22: 60.5M Q2 '22: 66.5M Q3 '22: 93.9M Q1 '23: 102.1M Q2 '23: 105.5M Q3 '23: 107M Q1 '24: 129.3M Q2 '24: 129.5M Q3 '24: 132.6M Q1 '25: 162.6M Q2 '25: 164M Q3 '25: 167.7M Q1 '26: 200.2M Q2 '26: 204M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '16: -2.08 Q4 '16: -2.41 Q1 '17: -2.95 Q2 '17: -3.35 Q3 '17: -3.52 Q4 '17: -3.84 Q1 '18: -4.20 Q2 '18: -4.52 Q3 '18: -4.88 Q4 '18: -5.06 Q1 '19: -5.16 Q2 '19: -5.15 Q3 '19: -5.35 Q4 '19: -5.71 Q1 '20: -5.73 Q2 '20: -5.66 Q3 '20: -5.04 Q4 '20: -3.85 Q1 '21: -3.33 Q2 '21: -2.96 Q3 '21: -2.22 Q4 '21: -2.37 Q1 '22: -2.13 Q2 '22: -1.97 Q3 '22: -2.27 Q4 '22: -2.11 Q1 '23: -1.76 Q2 '23: -1.34 Q3 '23: -0.85 Q4 '23: -0.55 Q1 '24: -0.52 Q2 '24: -0.57 Q3 '24: -1.11 Q4 '24: -0.70 Q1 '25: -0.75 Q2 '25: -0.81 Q3 '25: -0.66 Q4 '25: -1.21 Q1 '26: -1.05 Q2 '26: -1.08 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.